Diurnal Group plc operates as a specialty pharma company worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.56|
|52 Week High||UK£0.47|
|52 Week Low||UK£0.98|
|1 Month Change||-6.98%|
|3 Month Change||-11.11%|
|1 Year Change||-22.65%|
|3 Year Change||-49.55%|
|5 Year Change||-60.70%|
|Change since IPO||-63.40%|
Recent News & Updates
|DNL||GB Biotechs||GB Market|
Return vs Industry: DNL underperformed the UK Biotechs industry which returned 36% over the past year.
Return vs Market: DNL underperformed the UK Market which returned 22.6% over the past year.
Stable Share Price: DNL is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: DNL's weekly volatility (4%) has been stable over the past year.
About the Company
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe.
Diurnal Group Fundamentals Summary
|DNL fundamental statistics|
Is DNL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DNL income statement (TTM)|
|Cost of Revenue||UK£779.00k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.073|
|Net Profit Margin||-229.90%|
How did DNL perform over the long term?See historical performance and comparison
Is Diurnal Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DNL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DNL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DNL is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: DNL is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DNL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DNL is good value based on its PB Ratio (2.5x) compared to the GB Biotechs industry average (6.3x).
How is Diurnal Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).
Earnings vs Market: DNL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: DNL's is expected to become profitable in the next 3 years.
Revenue vs Market: DNL's revenue (48.6% per year) is forecast to grow faster than the UK market (5.5% per year).
High Growth Revenue: DNL's revenue (48.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DNL's Return on Equity is forecast to be high in 3 years time
How has Diurnal Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DNL is currently unprofitable.
Growing Profit Margin: DNL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DNL is unprofitable, but has reduced losses over the past 5 years at a rate of 5.7% per year.
Accelerating Growth: Unable to compare DNL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (19.9%).
Return on Equity
High ROE: DNL has a negative Return on Equity (-26.75%), as it is currently unprofitable.
How is Diurnal Group's financial position?
Financial Position Analysis
Short Term Liabilities: DNL's short term assets (£41.6M) exceed its short term liabilities (£4.2M).
Long Term Liabilities: DNL's short term assets (£41.6M) exceed its long term liabilities (£63.0K).
Debt to Equity History and Analysis
Debt Level: DNL is debt free.
Reducing Debt: DNL has no debt compared to 5 years ago when its debt to equity ratio was 12.5%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DNL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DNL has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 6% each year
What is Diurnal Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DNL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DNL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DNL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DNL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DNL's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Martin Whitaker, BSc, Ph D., serves as the Chief Executive Officer and Executive Director of Diurnal Group Plc since December 1, 2015. Dr. Whitaker serves as an Operations Director of Critical Pharmace...
CEO Compensation Analysis
Compensation vs Market: Martin's total compensation ($USD699.39K) is above average for companies of similar size in the UK market ($USD326.10K).
Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.
Experienced Board: DNL's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DNL insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.4%.
Diurnal Group plc's employee growth, exchange listings and data sources
- Name: Diurnal Group plc
- Ticker: DNL
- Exchange: AIM
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£94.586m
- Shares outstanding: 168.90m
- Website: https://www.diurnal.co.uk
Number of Employees
- Diurnal Group plc
- Cardiff MediCentre
- Heath Park
- South Glamorgan
- CF14 4UJ
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 21:19|
|End of Day Share Price||2021/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.